Fidelity Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

Fidelity Investments’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.02M	Buy	305,969 +27,233	+10%	+$634K	﹤0.01%	2223
2026 Q1	$6.57M	Buy	278,736 +73,312	+36%	+$1.87M	﹤0.01%	2208
2025 Q4	$5.97M	Buy	205,424 +37,450	+22%	+$959K	﹤0.01%	2223
2025 Q3	$3.17M	Buy	167,974 +17,244	+11%	+$272K	﹤0.01%	2388
2025 Q2	$2.11M	Sell	150,730 -11,719	-7%	-$164K	﹤0.01%	2471
2025 Q1	$2.54M	Sell	162,449 -22,110	-12%	-$311K	﹤0.01%	2370
2024 Q4	$2.57M	Buy	184,559 +13,340	+8%	+$146K	﹤0.01%	2361
2024 Q3	$1.59M	Buy	171,219 +34,884	+26%	+$344K	﹤0.01%	2463
2024 Q2	$1.27M	Sell	136,335 -4,763	-3%	-$43.1K	﹤0.01%	2460
2024 Q1	$1.4M	Sell	141,098 -1,081,306	-88%	-$8.07M	﹤0.01%	2422
2023 Q4	$3.95M	Sell	1,222,404 -7,039,638	-85%	-$19.1M	﹤0.01%	2123
2023 Q3	$43.9M	Sell	8,262,042 -950,744	-10%	-$8.09M	﹤0.01%	1295
2023 Q2	$87.8M	Buy	9,212,786 +50,356	+0.5%	+$559K	0.01%	1055
2023 Q1	$101M	Buy	9,162,430 +23,257	+0.3%	+$336K	0.01%	985
2022 Q4	$135M	Buy	9,139,173 +209,942	+2%	+$3.67M	0.01%	848
2022 Q3	$171M	Buy	8,929,231 +1,216,551	+16%	+$27.6M	0.02%	734
2022 Q2	$164M	Buy	7,712,680 +155,087	+2%	+$3.18M	0.02%	771
2022 Q1	$146M	Buy	7,557,593 +13,381	+0.2%	+$226K	0.01%	910
2021 Q4	$156M	Buy	7,544,212 +7,947	+0.1%	+$158K	0.01%	894
2021 Q3	$180M	Buy	7,536,265 +5,525	+0.1%	+$126K	0.01%	852
2021 Q2	$206M	Sell	7,530,740 -105,709	-1%	-$2.98M	0.02%	819
2021 Q1	$221M	Buy	7,636,449 +1,091,285	+17%	+$34.1M	0.02%	747
2020 Q4	$184M	Buy	6,545,164 +816,771	+14%	+$20M	0.02%	780
2020 Q3	$168M	Buy	5,728,393 +5,211	+0.1%	+$139K	0.02%	699
2020 Q2	$173M	Buy	5,723,182 +9,839	+0.2%	+$284K	0.02%	662
2020 Q1	$170M	Buy	+5,713,343	New	+$154M	0.02%	558

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fidelity Investments's ARQT Position: Q2 2026 in Review

Fidelity Investments increased its Arcutis Biotherapeutics (ARQT) stake by 9.8% in Q2 2026, buying an estimated $634K and bringing the position to 305,969 shares worth $8.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Fidelity Investments first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $221M in Q1 2021. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Fidelity Investments held 305,969 shares of Arcutis Biotherapeutics worth $8.02M as of Q2 2026.
Fidelity Investments bought 27,233 Arcutis Biotherapeutics shares in Q2 2026, an estimated $634K.
Arcutis Biotherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2223 holding.
Fidelity Investments first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
Fidelity Investments's Arcutis Biotherapeutics position peaked at $221M in Q1 2021.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.